T cell or T lymphocyte is a type of blood cell distinguished by its T cell receptor on the cell surface and plays a key role in the immune response.
-
JUL 26, 2023 | 3:10 PM
C.E. CREDITS
Cell-based immunotherapy has become the new-generation cancer medicine, and “off-the-shelf” cell products that can be manufactured at large scale and distributed readily to treat...
JUL 26, 2023 | 11:20 AM
C.E. CREDITS
Chimeric antigen receptor (CAR)-reprogrammed immune cells offer exciting therapeutic potential for addressing oncology, autoimmune diseases, transplant medicine, and infections. However, cur...
Achieving consistent AAV quantification with the QuantStudio Absolute Q AutoRun dPCR Suite Accurate quantification of AAV vectors is crucial for quality control and timely decision-making du...
The therapeutic use of chimeric antigen receptor T cells has achieved significant success in the treatment of B cells malignancies. Despite promising results in mouse tumor models, a similar...
MAY 09, 2023 | 1:00 PM
C.E. CREDITS
Date: May 09, 2023 Time: 5:00am (PDT), 8:00pm (EDT), 2:00pm (CEST) Advances in high content imaging (HCI) have improved the use of cell culture to make a large number of comparisons within i...
MAY 02, 2023 | 8:00 AM
C.E. CREDITS
Abstract Learning Objectives Define a tertiary lymphoid structure in human cancer Describe the tumor microenvironment factors that influence the formation of tertiary lymphoid structures Ide...
Date: March 30, 2023 Time: 5:00pm (PST), 8:00pm (EST) March 31, 2023 9:00am (JST) Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The q...
Have you ever tried to access the genomic profiles of cell lines before using them in your preclinical experiments just to come up empty-handed? Maybe you’ve scoured public databases f...
FEB 22, 2023 | 9:00 AM
C.E. CREDITS
Date: February 22, 2023 Time: 9:00am (PST), 12:00pm (EST), 6:00pm (CET) Circular plasmid DNA has traditionally been used as a stable and efficient vector for gene expression and HDR-mediated...
FEB 22, 2023 | 5:30 AM
C.E. CREDITS
Ninety percent of therapeutic agents reaching clinical trial fail to reach entry to market, with safety concerns being a major cause for failures in phase I and II clinical trials. Drug-indu...
FEB 22, 2023 | 5:30 AM
C.E. CREDITS
Many current technologies used in drug discovery and preclinical development programmes typically involve multi-step operations, extensive hands-on time, and lengthy liquid handling processe...